Hemab Therapeutics Holdings, Inc.

Healthcare · Biotechnology · United States

Last price 41.29 USD (Oct 30, 2026, 3:42 PM EDT) · Market cap 1.93B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale...